Abstract
Overview
Introduction
Parkinson' s disease (PD) is a progressive, degenerative condition of the
central nervous system that affects the way the brain coordinates body
movements, including walking, talking and writing. PD affects less than 1% of
the population in the seven major markets (7MM); with patients typically being
diagnosed in their early sixties and living for over 18 years after the onset
of first symptoms.
Scope
- Overview of epidemiology, presentation, and diagnostic assessment in PD
- Breakdown of first-line treatment regimens for early-, mid-, and
advanced-stage disease, with analysis of second-line add-on and switching
dynamics
- Influences on neurologists' treatment decisions and their perception of
current brands
- Evaluation of treatment outcomes and surgical procedures for PD
Highlights
Neurologists indicated that the DAs Mirapex (pramipexole) and Requip
(ropinirole) are generally the initial treatment of choice for younger
presenting patients. While levodopa is reserved for patients over 65 years of
age, neurologists may prescribe the MAOIs selegiline and rasagiline (Azilect)
in young patients with only mild symptoms at onset.
Neurologists indicated that only 36% of advanced-stage PD patients are
adequately controlled by pharmacological therapy. Considering the even
distribution of patient severities (30% early-stage, 39% mid-stage and 31%
advanced-stage), the advanced-stage patient group is particularly poorly
served by current therapies.
Neurologists estimated that approximately 9% of all PD patients will
eventually require surgery. Deep Brain Stimulation is by far the most common
surgical procedure used in the 7MM and neurologists indicated that over 70% of
patients receiving it experience both a reduction in PD symptoms and a
reduction in the dose of pharmacological medication.
Reasons to Purchase
- Target prescribers more effectively, through an understanding of
prescribing behavior and its influences
- Validate new product forecasting based on diagnosis and treatment rates,
and the likely rate of uptake for new products
- Benchmark brand awareness and perceptions surrounding product positioning
in order to formulate competitive lifecycle management strategies
| 
View Cart
